Vol 6, No 2 (2009)

Articles
Efficacy of metoprolol in treatment and preventive of cardiovascular diseases
Chazova I.E., Ratova L.G., Ratova L.G., Chazova I.E.
Abstract
Systemic Hypertension. 2009;6(2):4-7
views
Amlodipin in the treatment of arterial hypertension
Galyavich A.S.
Abstract
Systemic Hypertension. 2009;6(2):7-10
views
Perindopril in treatment of patients with arterial hypertension and high cardiovascular risk
Недогода С.В., Nedogoda S.V.
Abstract
Systemic Hypertension. 2009;6(2):10-15
views
Obstructive sleep apnea syndrome
Litvin A.Y., Chazova I.E.
Abstract
Systemic Hypertension. 2009;6(2):15-21
views
The intensive control of blood pressure: possibilities of the combined therapy.
Andrushchishina T.B., Morozova T.E.
Abstract
Systemic Hypertension. 2009;6(2):22-27
views
Arterial hypertension and sleep apnea in pediatrics: results of pilot trial
Madaeva I.M., Shevyrtalova O.N., Dolgikh V.V., Madaeva I.M., Shevyrtalova O.N., Dolgich V.V.
Abstract
Systemic Hypertension. 2009;6(2):28-31
views
Combined low-dose therapy of arterial hypertension
Stryuk R.I.
Abstract
Systemic Hypertension. 2009;6(2):31-34
views
Sartans in cardiological practice: new possibilities in therapy of cardiovascular diseases
Smolenskaya O.G.
Abstract
Systemic Hypertension. 2009;6(2):34-38
views
Perspectives of using angiotensin receptor antagonists
Fomin V.V.
Abstract
Systemic Hypertension. 2009;6(2):38-43
views
HYVET: landmark trial voted 2008 Trialof the Year by the ImpACT/Society for Clinical Trials and the American Heart Association
- -.
Abstract
Systemic Hypertension. 2009;6(2):44-45
views
Vozmozhnosti telmisartana v ANGIO- i KArdioprotektsii i uluchshenii pokazateley uglevodnogo obmena pri narushenii tolerantnosti k glyukoze
Nedogoda S.V., Barykina I.N., Brel' U.A., Chalyabi T.A., Mazina G.V., Podol'skaya E.V., Ledyaeva A.A.
Abstract
Systemic Hypertension. 2009;6(2):47-50
views
The level of uric acid and its role at early stages of essential hypertension
Oshchepkova E.V., Dmitriev V.A., Polovitkina O.V., Titov V.N.
Abstract
Aim: correlation of uric acid (UA) level on serum blood and urine with indicators of not specific inflammation and clinical characteristic in essential hypertension (EH) patients. Methods: 67 patients with EH (48 men) 30-65 years age (442) with stage 1 EH (n=37) and 2 (n=30) with moderate or high cardiovascular (CV) risk. The control group - 14 healthy peoples: (6 men) 45,52,1 years age with normal blood pressure (BP). The normal level of С-reactive protein (CRP) is less 3 mg/l. The normal level of UA in blood is 202,3-416,5 mkmol/l, and in urine is 1,48-4,43 mmol/24 hour. The estimates of creatinine clearance by the Cockroft-Gault formula. Results: the patients with EH have bigger level CRP, UA in blood and urine than healthy peoples with normal BP. Higher levels UA in blood and urine have patients even with early stages EH and moderate CV risk. The bigger level of UA in blood has EH patients with obesity and dyslipidaemia. The level of UA in blood and urine is higher at EH patients with hyperfiltration vs patients with normal creatinine clearance. Conclusion: the patients with early stage of EH have higher level of UA in blood and urine than healthy peoples with normal BP. The level of UA in blood and urine is correlated with dyslipidaemia. Key words: essential hypertension, uric acid, non specific inflammation
Systemic Hypertension. 2009;6(2):51-56
views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies